Last checked at 8 Jun 2018 07:00
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Investor presentation
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it will hold a presentation for investors on Tuesday 26th June 2018.
The briefing by Dr. Vladislav Sandler, CEO of Hemogenyx, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email hemogenyx@walbrookpr.com
Enquiries:
Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR | |
Sir Marc Feldmann, Chairman |
| |
|
| |
Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 | |
Christian Dennis |
| |
|
| |
Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 | |
Damon Heath, Erik Woolgar |
| |
|
| |
Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 | |
Lucy Williams/Duncan Vasey |
| |
|
| |
Walbrook PR Paul McManus | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com | |
| Mob: +44 (0)7980 541 893 | |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.